Baird Financial Group
TARS icon

Baird Financial Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Baird Financial Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Sell
38,898
-3,079
-7% -$197K ﹤0.01% 1026
2026
Q1 		$2.94M Sell
41,977
-4,951
-11% -$346K ﹤0.01% 909
2025
Q4 		$3.84M Sell
46,928
-6,950
-13% -$519K 0.01% 815
2025
Q3 		$3.2M Sell
53,878
-7,803
-13% -$384K 0.01% 885
2025
Q2 		$2.5M Sell
61,681
-49,111
-44% -$2.21M ﹤0.01% 938
2025
Q1 		$5.69M Sell
110,792
-31,627
-22% -$1.56M 0.01% 646
2024
Q4 		$7.89M Sell
142,419
-4,017
-3% -$182K 0.02% 569
2024
Q3 		$4.82M Buy
146,436
+22,658
+18% +$637K 0.01% 679
2024
Q2 		$3.36M Sell
123,778
-4,494
-4% -$151K 0.01% 792
2024
Q1 		$4.66M Buy
+128,272
New +$3.77M 0.01% 681

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Baird Financial Group's TARS Position: Q2 2026 in Review

Baird Financial Group reduced its Tarsus Pharmaceuticals (TARS) stake by 7.3% in Q2 2026, selling an estimated $197K and leaving 38,898 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1026.

Baird Financial Group first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.89M in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Baird Financial Group held 38,898 shares of Tarsus Pharmaceuticals worth $2.45M as of Q2 2026.
  • Baird Financial Group sold 3,079 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $197K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1026 holding.
  • Baird Financial Group first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Baird Financial Group's Tarsus Pharmaceuticals position peaked at $7.89M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.